NCT04584086 (BRAIN TEL) is a NA clinical trial of MRI 3 tesla in Benign Brain Tumors, sponsored by Centre Francois Baclesse.

Who is sponsoring NCT04584086?

NCT04584086 is sponsored by Centre Francois Baclesse.

What drugs are being tested in NCT04584086?

Interventions in NCT04584086: MRI 3 tesla.

What condition does NCT04584086 study?

NCT04584086 studies Benign Brain Tumors, Proton Therapy.

Is NCT04584086 still recruiting?

NCT04584086 is currently completed. Last updated 8 March 2023.

Last reviewed 2023-03-08 · How we verify

NCT04584086: BRAIN TEL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Changes in the MRI Signal in Patients With Benign Tumors of the Brain and Meninges Treated With Proton Therapy: Impact of TEL and the Biological Dose Received

Completed NA Last updated 8 March 2023

What this trial tests

NA trial testing MRI 3 tesla in Benign Brain Tumors in 20 participants. Completed in 27 February 2023.

Timeline

22 April 2021

Primary endpoint
27 February 2023

27 February 2023

Quick facts

Lead sponsor	Centre Francois Baclesse
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	20
Start date	22 April 2021
Primary completion	27 February 2023
Estimated completion	27 February 2023
Sites	1 location across France

Drugs / interventions tested

MRI 3 tesla

Conditions studied

Benign Brain Tumors — all drugs for Benign Brain Tumors →
Proton Therapy — all drugs for Proton Therapy →

Sponsor

Centre Francois Baclesse — full company profile →

Who can join

18 and older, any sex, with Benign Brain Tumors or Proton Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective is to detect with TESLA multiparametric 3 MRI, the MRI secondary changes to protontherapy irradiation and to correlate them with TEL mapping, physical dose and biological dose. A model should thus be able to be proposed at the end of the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MRI 3 tesla

Trials testing the same drug.

NCT04391933 — MRI Staging in Colon Cancer · NA · completed

Other Centre Francois Baclesse trials

Trials by the same sponsor.

NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
NCT06792721 — MEASUREMENT OF CIRCULATING MUTATION BURDEN · recruiting
NCT06817161 — Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar · Phase 3 · recruiting
NCT06612827 — Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions · recruiting
NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04584086 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Francois Baclesse
Last refreshed: 8 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04584086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing